Log In
BCIQ
Print this Print this
 

TS23

  Manage Alerts
Collapse Summary General Information
Company Translational Sciences Inc.
DescriptionBlood clot-dissolving antibody
Molecular Target Serpin peptidase inhibitor clade F member 2 (SERPINF2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationBlood clots
Indication DetailsBlood clots
Regulatory Designation
PartnerDaiichi Sankyo Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/15/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today